Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.
Exogenus Therapeutics strengthens IP portfolio with patent granted in China and Korea
Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in China and Korea. The...
Exogenus Therapeutics participates in Blue Bio Value’s Accelerator, aiming to bring blue-derived EV to the healthcare market
Exogenus Therapeutics was one of the 18 startups selected to take part in the Blue Bio Value Accelerator organized by Oceano Azul Foundation, Calouste Gulbekian Foundation and Maze. The...
Join Joana Correia at the 4th Exosome Based Therapeutic Development Summit
Exogenus Therapeutics CEO, Joana Simões Correia, is again an invited speaker at the 4th Exosome Based Therapeutic Development Summit, taking place in Boston, October 4th-6th. Joana’s talk...